The “Global TCR-based Therapy Market (2nd Edition), 2022-2035” report by Roots Analysis features an extensive study of the current market landscape and future potential of TCR-based therapies over the next decade.

Key Inclusions

• An executive summary of the insights captured during our research. It offers a high-level view on the current state of global TCR-based therapies market and its likely evolution in the mid-long term.
• A general overview of TCR-based therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in development of TCR-based therapies
• A detailed assessment of the overall market landscape of TCR-based therapies, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, and preclinical), therapeutic area (hematological cancer, solid tumor, and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, nasopharyngeal carcinoma, and others), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso, HLA, and others), source of T-cells (autologous / allogeneic), route of administration (intravenous and intratumoral), dosing frequency (single dose, multiple dose, and split dose), target patient segment (children, adults, and elderly patients), type of therapy (monotherapy and combination therapy) and most active players (in terms of number of TCR-based therapies). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this domain.
• A detailed analysis of popular target antigens, based on the number of TCR therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
• An analysis of completed, ongoing, and planned clinical studies related to TCR-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, most active players (in terms of number of registered trials), key focus areas and geography.
• An insightful analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TCR-based therapies, considering them to be KOLs, who are actively involved in R&D of TCR-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
• Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
• A detailed analysis of recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
• An analysis of the funding and investments that have been made into companies having proprietary TCR-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
• An in-depth analysis of patents related to TCR-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted, patent applications, and search reports), patent publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus area, type of player, leading player (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.
• A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
• A n elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TCR therapy that is likely to be marketed in the coming years.
• A review of the key promotional strategies that are being implemented by the developers of the approved TCR-based therapy (Kimmtrak®).
• Elaborate profiles of the leading players in the domain of TCR-based therapies. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TCR-based therapies, the technology portfolio (if available), recent developments related to TCR-based therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

• Target Indication(s)
• Nasopharyngeal Carcinoma
• Multiple Myeloma
• Head and Neck Carcinoma
• Sarcoma, Melanoma
• Acute Myeloid Leukemia
• Lung Cancer
• Ovarian Cancer
• Merkel Cell Cancer
• Target Antigen
• NY-ESO-1
• EBV
• gp100
• Others
• Key Geographical Regions 
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and North Africa
• Rest of the World 

Key Questions Answered

• What is the growth rate of TCR-based therapy market?
• Which region has the highest growth rate in the TCR-based Therapies market?
• Who are the leading industry and non-industry players in this market?
• How many players are developing TCR-based Therapies?
• Which target indication covers the largest TCR-based therapy market share?
• What is the partnership and collaboration trend in the TCR-based therapy domain?
• What is the current IP landscape of TCR-based therapies market?

To view more details on this report, click on the link:

https://www.rootsanalysis.com/reports/tcr-based-therapies-market.html

You may also be interested in the following titles:

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com